In breast cancer, febrile neutropenia-related admissions account for significant mortality
the ONA take:
According to a new study published in the journal Supportive Care in Cancer, researchers from the Reading Health System Department of Internal Medicine in West Reading, Pennsylvania, have found that febrile neutropenia-related hospitalizations still account for significant health care resource use, morbidity, and mortality among patients with breast cancer.
For the retrospective study, researchers sought to investigate the mean length of stay, incidence of morbidity and mortality, and health care costs associated with febrile neutropenia-related admissions of patients with breast cancer.
Researchers identified patients with breast cancer who were hospitalized for febrile neutropenia between 2009 and 2011 from the Nationwide Impact Sample database. Results showed that the mean length of stay was 5.7 days (95% CI: 5.5 - 5.9) and the mean cost of hospitalization was $37,087 (95% CI: 34,009 - 40,165).
They found that the average inhospital mortality rate during that period was 2.6% (n = 685), and age 65 years and older was associated with a higher risk of mortality (4.4% vs 1.7%; OR = 2.7; 95% CI: 2.3 - 3.1; P < 0.01). The findings suggest that febrile neutropenia accounts for significant mortality, and more effort needs to be made to reduce the cost of health care without decreasing the quality of care.
Febrile neutropenia-related hospitalizations still account for morbidity, and mortality among patients with breast cancer.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|